Fig. 1.

Increased expression of TLR1, TLR2 and TLR6 in monocytes of ovarian cancer patients. a Expression of TLR1-9 mRNA in PBMCs from ovarian cancer patients (OC; N = 24), benign disease patients (BC; N = 22) and healthy subjects (NC; N = 22). TLR2 and TLR6 mRNA expression levels were higher in PBMCs from ovarian cancer patients than in those from benign disease patients or healthy subjects. b The expression of TLR1, TLR2 and TLR6 in monocytes was analyzed by flow cytometry. The data shown were representative results of FACS analysis of monocytes from ovarian cancer patients, benign disease patients and healthy subjects. An isotype-matched antibody was served as a negative control. c The differential expression of TLR1, TLR2 and TLR6 in PBMCs cellular subsets was analyzed by flow cytometry. One-way ANOVA was used to assess the differences in expression of TLR1, TLR2 and TLR6 in cellular subsets of PBMCs from ovarian cancer patients, benign disease patients and healthy subjects. *P < 0.05 compared with healthy subjects; ^△ P < 0.05 compared with benign disease patients